Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The GM1 ganglioside—formally known as monosialotetrahexosylganglioside GM1—is a glycosphingolipid present on the surface of mammalian cells, including the small intestinal epithelial cells. It serves as the canonical receptor for the enterotoxigenic Escherichia coli (ETEC) heat-labile toxin, as well as cholera toxin, by binding the toxin’s B subunit and facilitating its entry into the host cell[4]. This interaction triggers signaling cascades that ultimately lead to the secretory diarrhea characteristic of ETEC infections[2][4]. GM1’s role as a toxin receptor makes it an attractive but challenging therapeutic target, with most strategies focusing on inhibiting toxin binding or enhancing host immunity rather than directly modulating GM1 itself[2][4].
Drugs or molecules that prevent ETEC heat-labile toxin or cholera toxin from binding GM1 can block toxin-induced diarrhea Mechanistic vaccines or neutralizing antibodies act by interruption of toxin-receptor interaction
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Monosialotetrahexosylganglioside GM1 receptor (GM1).